Daiichi Sankyo and Ranbaxy to Expand Hybrid Business Model in Mexico
Tokyo Japan and Gurgaon India (August 2, 2011) -- Daiichi Sankyo
Company, Limited (hereafter, Daiichi Sankyo) and Ranbaxy
Laboratories Limited (hereafter, Ranbaxy) today announced the
expansion of business in Mexico to maximize their Hybrid Business
Model, encompassing both innovative and affordable, high quality,
generic medicines.
Daiichi Sankyo and Ranbaxy (collectively “the Group”)
have agreed to expand the Group’s business in Mexico with the
launch of Olmesartan medoxomil. The product is expected to be
introduced to the market before the end of 2011. Daiichi Sankyo
Mexico S.A. de C.V (DSMX), a newly established subsidiary of
Daiichi Sankyo, and Ranbaxy Mexico S.A de C.V. (RMEX) will leverage
the Group’s Hybrid Business Model in Mexico by utilizing the
business know-how and cost advantage of Ranbaxy, thereby offering
both innovative and affordable, high quality generic
medicines.
“We are pleased to announce the synergistic business
development with Ranbaxy in Mexico,” said Joji Nakayama,
President & CEO of Daiichi Sankyo. “We are determined to
work with Ranbaxy to further serve diversifying medical needs in
this strongly emerging market.”
Commenting on the development, Arun Sawhney, Managing Director of
Ranbaxy, said, “Mexico is an important
emerging market for us, and
Ranbaxy and Daiichi Sankyo will
work together in providing innovative options and
solutions to customers through the Hybrid Business
Model.”
Daiichi Sankyo and Ranbaxy will continue to reinforce their
respective and consolidated business platforms over the longer term
by further accelerating their global business coordination.
About Olmesartan medoxomil
Olmesartan medoxomil is a member of the angiotensin receptor
blocker (ARB) class of antihypertensive medications that help lower
blood pressure by blocking the angiotensin II receptor on the blood
vessels and antagonizing the release of the hormone which causes
salt retention and increased blood volume.
Olmesartan medoxomil is available in more than 60 countries
worldwide. About RMEX RMEX, a subsidiary of Ranbaxy, has already
been delivering a strong portfolio of generic medicines for a wide
range of therapeutic segments in Mexico. In October 2009, RMEX
created a division for the future introduction of Daiichi Sankyo's
innovator products into the Mexican market. With an estimated
population of 107 million people, Mexico is the 14th largest
pharmaceutical market in the world, and is the second largest in
Latin America. The size of the pharmaceutical market in Mexico is
approximately USD $11.4 billion (2010).
About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of
innovative pharmaceutical products to address the diversified,
unmet medical needs of patients in both mature and emerging
markets. While maintaining its portfolio of marketed
pharmaceuticals for hypertension, hyperlipidemia, and
bacterial
infections, the Group is engaged in the development of treatments
for thrombotic disorders and focused on the discovery of novel
oncology and cardiovascular-metabolic therapies. Furthermore, the
Daiichi Sankyo Group has created a "Hybrid Business Model," which
will respond to market and customer diversity and optimize growth
opportunities across the value chain. For more information, please
visit www.daiichisankyo.com
About Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited, India's largest pharmaceutical
company, is an integrated, research based, international
pharmaceutical company producing a wide range of quality,
affordable generic medicines, trusted by healthcare professionals
and patients across geographies. Ranbaxy’s continued focus on
R&D has resulted in several approvals in developed markets and
significant progress in New Drug Discovery Research. The
Company’s foray into Novel Drug Delivery Systems has led to
proprietary "platform technologies," resulting in a number of
products under development. The Company is serving its
customers in over 125 countries and has an expanding international
portfolio of affiliates, joint ventures and alliances, ground
operations in 46 countries and manufacturing operations in 7
countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi
Sankyo is a leading global pharma innovator,
headquartered in Tokyo, Japan.
For further information, please contact:
Daiichi Sankyo Company, Limited
3-5-1, Nihonbashi Honcho,
Chuo-ku,Tokyo 103-8426, Japan
Toshiaki Sai
Corporate Officer - Corporate Communications
Masaya Tamae
Director - Public Relations
Tel: +81-3-6225-1126
Shigemichi Kondo
Director - Investor Relations
Tel: +81-3-6225-1126
Ranbaxy Laboratories Limited
Plot 90, Sector 32, Gurgaon
Haryana 122001, India
Ramesh L. Adige
President - Corporate Affairs and
Global Corporate Communications
email: ramesh.adige@ranbaxy.com
Tel: +91-124-4135000
Raghu Kochar
Director-Corporate Communications
email: raghu.kochar@ranbaxy.com
Tel: +91-124-4135141
Mobile: 9811617256
Krishnan Ramalingam
General Manager-Corporate Communications
email: krishnan.ramalingam@ranbaxy.com
Tel: +91-124-4135143
Mobile: 9810042540
Posted: August 2011
